DMC’s technology enables reproducibility and robustness to scale; Production of a diversity of targets using a single bioprocess; HTS approaches that translate to full scale performance — and the company says, “50X improvement in speed and cost of product development.” The business model? Specialty chemicals, nutrition products, and pharmaceuticals, with a focus on partner agreements to quickly generate revenue and validate the technology; eventually, commercialization through strategic partnerships and existing supply chains.
DMC CEO Matt Lipscomb gave this illuminating presentation at ABLC Next 2016 in San Francisco.
